¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tissue plasminogen activation inhibitor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
¿µ¹® tissue ÇÑ±Û Á¶Á÷
¼³¸í   
  Æ¯Á¤ ±¸Á¶¿Í ±â´ÉÀ» °®´Â ¼¼Æ÷ Áý´Ü. ¼¼Æ÷ »çÀÌ¿¡´Â ´Ù¼Ò°£ ¼¼Æ÷°£ÁúÀÌ µé¾î ÀÖ´Ù. ¼¼Æ÷°£Áú¿¡´Â ±Û¸®ÄÚ»ç¹Ì³ë±Û¸®Ä­, È÷µå·Ï½Ã¾ÆÆÄŸÀÌÆ®¿Í °°Àº ±âÁú°ú ¾Æ±³Áú¼¶À¯¿Í °°Àº ¼¶À¯°¡ ¹ß°ßµÈ´Ù. Á¶Á÷¼º»óÀº ±¸¼º¼¼Æ÷¿Í ¼¼Æ÷°£ÁúÀÇ Á¾·ù¿Í ¾ç¿¡ ÀÇÇØ °áÁ¤µÈ´Ù. Á¶Á÷Àº »óÇÇÁ¶Á÷, ÁöÁöÁ¶Á÷, ±ÙÀ°Á¶Á÷, ½Å°æÁ¶Á÷À¸·Î ´ëº°µÇ¸ç, »óÇÇÁ¶Á÷Àº ¼¼Æ÷°£ÁúÀ» °ÅÀÇ °®Áö ¾ÊÀ¸¸ç, ÁöÁöÁ¶Á÷Àº °áÇÕÁ¶Á÷À̳ª »ÀÁ¶Á÷°ú °°ÀÌ ¼¼Æ÷°£ÁúÀ̠dzºÎÇÑ °ÍÀÌ ¸¹´Ù.
¿µ¹® tissue biopsy ÇÑ±Û Á¶Á÷»ý°Ë
¼³¸í   
  È¯ÀÚÀÇ º´ÀûÀΠÁ¶Á÷ÀÇ ÀϺθ¦ ¶¼¾î ³»¼­ º´¸®Á¶Á÷Ç¥º»À» ¸¸µé¾î¼­ Çö¹Ì°æÀûÀ¸·Î °Ë»çÇϴ °Í. ¿Ü°úÀû ¼ö¼úÀç·á·ÎºÎÅÍ º´¸®Á¶Á÷ÇÐÀû °Ë»ç¸¦ ÇÏ¿© »ýü³»ÀÇ º´º¯À» Ãß±¸Çϴ ºÐ¾ß¸¦ ¿Ü°úº´¸®ÇÐÀ̶ó°í ÇÑ´Ù. »ý°Ë¿¡´Â ½û±â»ý°Ë, ÃµÀÚħ»ý°Ë, ²ç¶Õ±â½Ä»ý°Ë, ³»½Ã°æ»ý°Ë ¿Ü¿¡ ¼¼Æ÷ÁøÀ̶ó°í ºÒ¸®¿ì´Â ¹Ú¸®¼¼Æ÷ÁøÀ̳ª ¼¼Ã´¼¼Æ÷Áø µî ¶³¾îÁø ¼¼Æ÷¸¦ µµ¸»°Ë»çÇϴ ¹æ¹ýÀÌ Æ÷ÇԵȴÙ.
¿µ¹® target tissue ÇÑ±Û Ç¥ÀûÁ¶Á÷
¼³¸í   
  È£¸£¸ó¿¡ ´ëÇÏ¿© Ç¥ÀûÀÌ µÇ´Â ¼¼Æ÷¶ó´Â Àǹ̷μ­ ±× È£¸£¸ó¿¡ ´ëÇÑ ¼ö¿ëü¸¦ °¡Áö°í Àִ ¼¼Æ÷. ¿¹¸¦ µé¾î Àν¶¸°Àº Àν¶¸° ¼ö¿ëü¸¦ °¡Áø ¼¼Æ÷¸¦ Ç¥Àû¼¼Æ÷·Î ÇÏ¿© ÀÌ ¼¼Æ÷¿¡¸¸ ÀÛ¿ëÇÑ´Ù.
¿µ¹® subcutaneous tissue, subcutis ÇÑ±Û ÇÇÇÏÁ¶Á÷
¼³¸í   
  ÇǺο¡¼­ ÁøÇÇÀÇ ¾Æ·§ºÎºÐÀ» ¸»ÇÔ. ¿©±â¿¡´Â Áö¹æÁ¶Á÷ÀÌ ¸¹´Ù. ±â´ÉÀº ¿­ÀÇ °Ý¸®, Ãæ°ÝÈí¼ö, ¿µ¾çÀúÀå¼Ò µîÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • competitive inhibitor
    °æÀï¾ïÁ¦Á¦
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼Ò¾ïÁ¦Á¦
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • corrosion inhibitor
    ºÎ½Ä¾ïÁ¦Á¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • inhibitor
    1. ¾ïÁ¦Á¦ 2. ¾ïÁ¦ÀÎÀÚ
  • mitotic inhibitor
    À¯»çºÐ¿­¾ïÁ¦Á¦
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
  • oocyte maturation inhibitor
    ³­ÀÚ¼º¼÷¾ïÁ¦ÀÎÀÚ
  • polymerization inhibitor
    ÁßÇÕ¾ïÁ¦Á¦
  • protease inhibitor
    ´Ü¹éÁúºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor
    ƯÀ̼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lymphatic tissue
    ¸²ÇÁÁ¶Á÷
  • mesenchymal tissue
    Áß°£¿±Á¶Á÷
  • muscular tissue
    ±ÙÀ°Á¶Á÷
  • nervous tissue
    ½Å°æÁ¶Á÷
  • osseous tissue
    »ÀÁ¶Á÷
  • osteoid tissue
    »À¸ð¾çÁ¶Á÷, Dz»ÀÁ¶Á÷
  • retained placental tissue
    ÀÜ·ùŹÝÁ¶Á÷
  • reticular tissue
    ±×¹°Á¶Á÷, ¼¼¸ÁÁ¶Á÷
  • scar tissue
    ÈäÅÍÁ¶Á÷
  • soft tissue
    ¿¬Á¶Á÷, ¹°··Á¶Á÷
  • subcutaneous tissue
    ÇǺιØÁ¶Á÷, ÇÇÇÏÁ¶Á÷
  • tissue typing
    Á¶Á÷Çü°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • coagulation factor inhibitor
    ÀÀ°íÀÎÀÚ¾ïÁ¦Á¦
  • competitive inhibitor
    °æÀï¾ïÁ¦Á¦
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • corrosion inhibitor
    ºÎ½Ä¾ïÁ¦Á¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • inhibitor
    ¾ïÁ¦Á¦
  • inhibitor substance
    ¾ïÁ¦¹°Áú
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
  • mitotic inhibitor
    Çٺп­¾ïÁ¦Á¦
  • oocyte maturation inhibitor
    ³­ÀÚ¼º¼÷¾ïÁ¦ÀÎÀÚ
  • particle-enhanced turbidimetric inhibitor
    ÀÔÀÚÁõ´ëȥʾïÁ¦Á¦
  • polymerization inhibitor
    ÁßÇÕ¾ïÁ¦Á¦
  • protease inhibitor
    ´Ü¹éºÐÇØÈ¿¼Ò¾ïÁ¦Á¦
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activation, polyclonal
    ´Ù¼¼Æ÷±ºÈ°¼º, ¿©·¯¹«¸®È°¼º
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • heat of activation
    Ȱ¼ºÈ­¿­(üÀàõûýæð)
  • photochemical activation
    ±¤È°¼ºÈ­(Ë´Ì· ËÛÌ´).
  • polyclonal B cell activation
    B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
  • ACEI : angiotensin converting enzyme inhibitor
    ¾ÈÁö¿ÀÅÙ½ÅÀüȯȿ¼Ò¾ïÁ¦Á¦(ï®ü½ý£áÈåäð¤ð¥).
  • CAI=£¾carbonic anhydrase inhibitor
    ź»êÅ»¼öÈ¿¼ÒÀúÇØ¾à, ź»êÅ»¼öÈ¿¼ÒÀúÇØ¹°Áú.
  • Inhibitor substance
    ¾ïÁ¦¹°Áú(åäð¤Úªòõ)
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î»êÈ­È¿¼Ò ¾ïÁ¦Á¦.
  • MAO inhibitor
    ¸ð³ë¾Æ¹Î »êÈ­È¿¼Ò ÀúÇØÁ¦.
  • MAO inhibitor(MAOI)
    ´Ü°¡¾Æ¹Î»êÈ­È¿¼Ò¾ïÁ¦Á¦
  • RIMA, see reversible inhibitor of MAO-A
    °¡¿ªÀû ´Ü°¡¾Æ¹Î-A »êÈ­È¿¼Ò¾ïÁ¦Á¦
  • acetylcholinesterase inhibitor
    ¾Æ¼¼Æ®Äݸ°¿¡½ºÅÍ·¹À̽º<¿¡½ºÅ×¶óÁ¦> ¾ïÁ¦Á¦.
  • activated protein C inhibitor
    Ȱ¼ºÈ­´Ü¹éÁú C ¾ïÁ¦Á¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation detector
    Ȱ¼ºÈ­ ŽÁö±â
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation gate
    °³¹æ °ü¹®(ËÒÛÁμڦ)
  • activation process
    Ȱ¼ºÈ­°úÁ¤.
  • activation, polyclonal
    ´Ù¼¼Æ÷±ºÈ°¼º, ¿©·¯¹«¸®È°¼º
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • c3, activation
    C3, Ȱ¼º (¡­üÀàõ)
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë(¡­üÀàõíÂéÄ), º¸Ã¼È°¼ºÈ­.
  • complement activation
    º¸Ã¼È°¼ºÀÛ¿ë
  • energy of activation
    Ȱ¼ºÈ­¿¡³ÊÁö.
  • heat of activation
    Ȱ¼ºÈ­¿­(üÀàõûýæð)
  • islet-activation factor
    ¶û°Ô¸£Çѽº»ù Ȱ¼ºÀÎÀÚ, ¹éÀÏÇØ±Õµ¶¼Ò
  • macrophage,activation of
    Ȱ¼ºÈ­(üÀàõûù)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Conducting tissue of heart
    ½ÉÀåÀüµµÁ¶Á÷
    [¿¾ ¿ë¾î] ½ÉÀåÀüµµ°è
  • Collagenous connective tissue
    ¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ±³¿ø°áÇÕÁ¶Á÷
  • Cartilage tissue
    ¿¬°ñÁ¶Á÷ [¹°··»ÀÁ¶Á÷]
    [¿¾ ¿ë¾î] ¿¬°ñÁ¶Á÷
  • Submucosal tissue
    Á¡¸·¹ØÁ¶Á÷
    [¿¾ ¿ë¾î] Á¡¸·ÇÏÁ¶Á÷
  • Abnormality of tissue
    Á¶Á÷ÀÌ»ó
    [¿¾ ¿ë¾î] Á¶Á÷ÀÌ»ó
  • Notochordal tissue (Chordoma)
    ô»èÁ¶Á÷ (ô»èÁ¾)
    [¿¾ ¿ë¾î] ô»èÁ¶Á÷
  • Lamellar bone tissue
    ÃþÆÇ»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] ÃþÆÇ¼º°ñÁ¶Á÷
  • Compact bone tissue
    Ä¡¹Ð»ÀÁ¶Á÷
    [¿¾ ¿ë¾î] Ä¡¹Ð°ñÁ¶Á÷
  • Dense collagenous connective tissue
    Ä¡¹Ð¾Æ±³°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] Ä¡¹Ð°áÇÕÁ¶Á÷
  • Renal tissue (Nephroblastoma)
    ÄáÆÏÁ¶Á÷ (ÄáÆÏ¸ð¼¼Æ÷Á¾)
    [¿¾ ¿ë¾î] ½ÅÁ¶Á÷
  • Elastic connective tissue
    ź·Â°áÇÕÁ¶Á÷
    [¿¾ ¿ë¾î] ź·Â°áÇÕÁ¶Á÷
  • Prechondral tissue
    Dz¿¬°ñÁ¶Á÷
    [¿¾ ¿ë¾î] Àü¿¬°ñÁ¶Á÷
  • Subcutaneous tissue
    ÇǺιØÁ¶Á÷
    [¿¾ ¿ë¾î] ÇÇÇÏÁ¶Á÷
  • Angioblastic tissue
    Ç÷°ü¹ß»ýÁ¶Á÷
    [¿¾ ¿ë¾î] Ç÷°ü¸ðÁ¶Á÷
  • Connective tissue fibers
    °áÇÕÁ¶Á÷¼¶À¯
    [¿¾ ¿ë¾î] °áÇÕÁ¶Á÷¼¶À¯
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fatty acid activation
    Áö¹æ»ê Ȱ¼ºÈ­ (ò·Û¸ß«üÀàõûù)
  • feed-forward activation
    ¾Õ¸ÔÀÓ È°¼ºÈ­ (üÀàõûù)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • neutron activation alalysis
    Áß¼ºÀÚ ¹æ»çÈ­ºÐ¼®(ñéàõí­Û¯ÞÒûùÝÂà°)
  • primary tissue culture
    ÀÏÂ÷ Á¶Á÷¹è¾ç(ìéó­ðÚòÄÛÆå×)
  • reciprocal activation
    »óº¸ Ȱ¼ºÈ­(ßÓÜÍüÀàõûù)
  • tissue culture
    Á¶Á÷¹è¾ç (ðÚòÄÛÆå×)
  • tissue culture infectious dose
    Á¶Á÷¹è¾ç °¨¿°·® (ðÚòÄÛÆå×ÊïæøÕá)
  • tissue factor
    Á¶Á÷ÀÎÀÚ (ðÚòÄì×í­)
  • tissue hormone
    Á¶Á÷(ðÚòÄ)È£¸£¸ó
  • tissue polypeptide antigen
    Á¶Á÷(ðÚòÄ)Æú¸®ÆéŸÀ̵å Ç׿ø (ù÷ê«)
  • tissue slice
    Á¶Á÷ õ¿± (ðÚòÄô¼ç¨)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • osteoblastic tissue
    °ñÇü¼ºÁ¶Á÷
  • proper connective tissue
    °íÀ¯°áÇÕÁ¶Á÷
  • pseudogating in flowing tissue
    À¯µ¿Á¶Á÷¿¡¼­ À§°ÔÀÌÆÃ
  • reticular connective tissue
    ¼¼¸Á°áÇÕÁ¶Á÷
  • reticular tissue
    ¼¼¸ÁÁ¶Á÷
  • retropharyngeal soft tissue space
    ÀεÎÈĺο¬ºÎÁ¶Á÷
  • scar tissue
    ¹ÝÈçÁ¶Á÷
  • soft tissue
    ¿¬Á¶Á÷
  • soft tissue calcification
    ¿¬Á¶Á÷¼®È¸È­
  • soft tissue technique
    ¿¬Á¶Á÷±â¹ý
  • stationary tissue
    Á¤Á¶Á÷
  • surrounding tissue
    ÁÖÀ§Á¶Á÷
  • tissue
    Á¶Á÷
  • tissue anoxia
    Á¶Á÷¹«»ê¼ÒÁõ
  • tissue characterization
    Á¶Á÷Ư¼º°¨º°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PAI patient assessment instrument; plasminogen activator inhibitor
PAI-1 plasminogen-activator inhibitor-1
rt-PA recombinant tissue-Plasminogen Activator
  = Alteplase
tPA tissue Plasminogen Activator
GUSTO Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TPA Tissue Plasminogen Activator
t-PA Ag Tissue plasminogen activator antigen
tPA Tissue plasminogen activator antigen
TPA Tissue-type plasminogen activator
t-PA:Ag Tissue-type plasminogen activator antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • coagulation factor inhibitor
    ÀÀ°í ÀÎÀÚ ¾ïÁ¦Á¦
  • collagenase inhibitor
    Äݶó°Ô³ªÁ¦ ¾ïÁ¦ ¹°Áú
  • cyclooxygenase inhibitor
    »çÀÌŬ·Î¿Á½ÃÁö³×ÀÌÁî ¾ïÁ¦Àç
  • dopa decarboxylase inhibitor
    µµÆÄ µ¥Ä«¸£º¹½Ç·¹À̽º ¾ïÁ¦ÀÚ
  • lipoxygenase inhibitor
    ¸®ÆÜ½ÃÁö³×À̽º ¾ïÁ¦Á¦
  • metabolic inhibitor
    ´ë»ç ÀúÇØÁ¦, ´ë»ç ¾ïÁ¦Á¦
  • polymerization inhibitor
    ÁßÇÕ ±ÝÁöÁ¦
    ÁßÇÕ ¹ÝÀÀÀ» ¹æÇØÇϱ⵵ Çϰí, ÁßÁöÇÒ ¼ö ÀÖ´Â ¹°Áú.
  • virus hemagglutination inhibitor
    ¹ÙÀÌ·¯½º ÀûÇ÷±¸ ÀÀÁý¹ÝÀÀ ¾ïÁ¦ ÀÎÀÚ
  • aberrant breast tissue
    ¹ÌÀÔ À¯¹æ Á¶Á÷
  • absorptive tissue
    Èí¼ö Á¶Á÷
  • acute and late normal tissue effects£¨Á¤»ó Á¶Á÷ ±Þ¼º ¿µÇ⣩

    acute angle

    ¿¹°¢
    Á÷°¢º¸´Ù ÀÛÀº °¢.
  • adenoid tissue
    ¾Æµ¥³ëÀ̵å Á¶Á÷
  • adipose tissue disease
    Áö¹æ Á¶Á÷ Áúȯ
  • bone tissue
    »À Á¶Á÷, °ñ Á¶Á÷
  • bony tissue
    °ñ¼º Á¶Á÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
amino acid activation The first step of protein synthesis, whereby an amino acid reacts with adenosine triphosphate in the presence of aminoacyl RNA synthetase to produce an amino acid adenylate, which provides the energy necessary for the attachment of the amino acid to a specific transfer RNA molecule.
(12 Dec 1998)
macrophage activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants.
(12 Dec 1998)
gene activation The process of activation of a gene so that it is expressed at a particular time. This process is crucial in growth and development.
(05 Mar 2000)
Gibbs energy of activation The Gibbs energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction.
(05 Mar 2000)
virus activation The mechanism by which latent viruses, such as genetically transmitted tumour viruses or prophages of lysogenic bacteria, are induced to replicate and are released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell lipopolysaccharides, glucocorticoid hormones, halogenated pyrimidines, ionizing radiation, ultraviolet light, and superinfecting viruses.
(12 Dec 1998)
cis activation <molecular biology> Activation of a gene by an activator located on the same chromosome i.e. Not by a diffusible product.
(18 Nov 1997)
complement activation The sequential activation of serum components c1 through c9, initiated by an erythrocyte-antibody complex or by microbial polysaccharides and properdin, and producing an inflammatory response.
(12 Dec 1998)
platelet activation A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug.
(12 Dec 1998)
neutron activation analysis Activation analysis in which the specimen is bombarded with neutrons. Identification is made by measuring the resulting radioisotopes.
(12 Dec 1998)
neutrophil activation The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonised particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil.
(12 Dec 1998)
EEG activation The low voltage, fast pattern of attentive wakefulness.
(05 Mar 2000)
trans-activation (genetics) Increased rate of gene expression directed by either viral or cellular proteins. These regulatory factors (diffusible gene products) act in trans -- that is, act on homologous or heterologous molecules of DNA. (cis-acting factors act only on homologous molecules.)
(12 Dec 1998)
energy of activation Energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction; usually expressed in the Arrhenius equation relating a rate constant to absolute temperature.
(05 Mar 2000)
enzyme activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1) activation by ions (activators); 2) activation by cofactors (coenzymes); and 3) conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
(12 Dec 1998)
juxtacrine activation Activation of target cells by membrane anchored growth factors, also used for activation of leucocytes by PAF bound to endothelial cell surface.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á